SCHEMBL12431107

SCHEMBL12431107

c1ccc(OCc2cc3ccccc3c(Nc3cc(C4CC4)[nH]n3)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 3/20 0.52
SRC P12931 2/20 0.51
CCNA2 P20248 2/20 0.51
CDK2 P24941 2/20 0.51
GSK3B P49841 2/20 0.51
ULK1 O75385 1/20 0.50
PAK4 O96013 1/20 0.50
PAK1 Q13153 1/20 0.50
IGF1R P08069 6/20 0.48
NTRK3 Q16288 1/20 0.48
NTRK2 Q16620 1/20 0.48
NEK1 Q96PY6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12431109 0.87 NTRK1 (0.53) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL13054902 0.85 NTRK1 (0.42) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL12431112 0.84 NTRK1 (0.57) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL12430762 0.83 NTRK1 (0.59) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL13054907 0.76 NTRK1 (0.45) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL12430684 0.76 NTRK1 (0.68) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL786513 0.74 ULK1 (0.65) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL29618398 0.74 ULK1 (0.65) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL27239850 0.73 PAK4 (0.53) NTRK1SRCCCNA2CDK2GSK3B
SCHEMBL14423491 0.73 NTRK1 (0.48) NTRK1SRCCCNA2CDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA NTRK1 2111/4885SRC 298/4885CCNA2 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.